Vaccinex, Inc. (VCNX)

Compare

0.7600

+0.0600

+(8.57%)

At close: 9:37:11 AM EDT

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

Following equity shortcomings, Vaccinex ends its journey as a public company after six and a half years.

Pharmaceutical Technology 23 days ago

VCNX
+8.57%
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasd

GlobeNewswire 26 days ago

VCNX
+8.57%
Top Midday Decliners

Vaccinex (VCNX) shares will be delisted from the Nasdaq stock exchange on Wednesday after the compan

PREMIUM
MT Newswires 3 months ago

VCNX
+8.57%
RVPHW
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

The company failed to meet the $2.5 million equity requirement under Nasdaq rules.

GuruFocus.com 3 months ago

VCNX
+8.57%
Vaccinex Announces Receipt of Delisting Notification from Nasdaq

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq

GlobeNewswire 3 months ago

VCNX
+8.57%
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer

GlobeNewswire 4 months ago

VCNX
+8.57%
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discoveryROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil,

GlobeNewswire 4 months ago

VCNX
+8.57%
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer.ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that

GlobeNewswire 4 months ago

VCNX
+8.57%
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s diseaseROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Vaccinex recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in earl

GlobeNewswire 4 months ago

VCNX
+8.57%
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s diseaseROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new efficacy and safety data for its ran

GlobeNewswire 5 months ago

VCNX
+8.57%
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) a

GlobeNewswire 6 months ago

VCNX
+8.57%
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Our Company recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer’s disease (AD). The

GlobeNewswire 7 months ago

VCNX
+8.57%
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint

The positive topline results demonstrated no serious treatment emergent adverse events.

Clinical Trials Arena 7 months ago

VCNX
+8.57%
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington’s disease based on similarities to neuroimmune pathology in Alzheimer’s ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer’s disease (AD) with anti-Semaphorin 4D (SEMA

GlobeNewswire 7 months ago

VCNX
+8.57%
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzhei

GlobeNewswire 8 months ago

VCNX
+8.57%
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that the last pati

GlobeNewswire 9 months ago

VCNX
+8.57%
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and prov

GlobeNewswire 10 months ago

VCNX
+8.57%

Performance Overview

Return	VCNX	S&P 500 (^GSPC)
YTD	-22.45%	-3.58%
1-Year	-88.64%	+8.94%
3-Year	-99.72%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vaccinex, Inc. (VCNX)

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Top Midday Decliners

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Performance Overview